Scarica l'app Stockscreener
1.20
2.56%
0.03
Precedente Chiudi:
$1.17
Aprire:
$1.18
Volume 24 ore:
109.88K
Relative Volume:
0.54
Capitalizzazione di mercato:
$12.10M
Reddito:
$200.00K
Utile/perdita netta:
$-11.46M
Rapporto P/E:
-0.328
EPS:
-3.6582
Flusso di cassa netto:
$-9.76M
1 W Prestazione:
-1.64%
1M Prestazione:
+1.69%
6M Prestazione:
-25.93%
1 anno Prestazione:
-49.37%
Intervallo 1D:
$1.16
$1.20
Intervallo di 1 settimana:
$1.15
$1.2396
Portata 52W:
$1.02
$6.2299
Soligenix Inc Stock (SNGX) Company Profile
Nome
Soligenix Inc
Settore
Industria
Telefono
609-538-8200
Indirizzo
29 EMMONS DRIVE, PRINCETON
Compare SNGX vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
1.20 | 12.10M | 200.00K | -11.46M | -9.76M | -3.6582 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-07-28 | Downgrade | Dawson James | Buy → Neutral |
| 2018-01-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | Reiterato | Maxim Group | Buy |
| 2017-07-17 | Iniziato | H.C. Wainwright | Buy |
Soligenix Inc Borsa (SNGX) Ultime notizie
Soligenix (SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach - NewMediaWire
Soligenix (NASDAQ: SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones Approach - TradingView
Soligenix (NASDAQ: SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting - Benzinga
Soligenix (SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation - NewMediaWire
Soligenix (NASDAQ: SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation Designation - Benzinga
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 - Nasdaq
HyBryte Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 - Bitget
Soligenix (SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication - NewMediaWire
Soligenix (NASDAQ: SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal Publication - Digital Journal
Soligenix (SNGX) Highlights HyBryte's Promise in Treating Early-Stage CTCL - GuruFocus
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc. - The Manila Times
IBN Announces Latest Episode of The BioMedWire Podcast - GlobeNewswire
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs" - ChartMill
Soligenix's HyBryte Clinical Data Published in Peer-Reviewed Journal, Supporting Potential as First-Line CTCL Treatment - citybuzz -
Soligenix Inc expected to post a loss of 56 cents a shareEarnings Preview - TradingView
Total debt per share of Soligenix, Inc. – LSE:0A6I - TradingView
Soligenix (NASDAQ: SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behçet Disease - USA Today
Earnings Risk: Should you avoid Soligenix Inc stock right now2026 Trends & Verified Chart Pattern Signals - baoquankhu1.vn
SNGX: Important Upcoming Readouts in Phase 3 CTCL Study - Smartkarma
Soligenix receives UK regulatory designation for Behçet’s drug By Investing.com - Investing.com Canada
Soligenix (SNGX) SGX945 Granted Promising Innovative Medicine Designation in UK for Behcet Disease - NewMediaWire
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency - Lelezard
Soligenix receives UK regulatory designation for Behçet’s drug - Investing.com
Soligenix (SNGX) Receives UK Nod for Innovative Behcet's Disease Treatment - GuruFocus
Soligenix Announces SGX945 Receives Promising Innovative Medicin - GuruFocus
Soligenix (SNGX) Leverages Platform Science for Broader Therapeutic Reach - NewMediaWire
Soligenix (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach - TradingView
SNGX SEC FilingsSoligenix Inc 10-K, 10-Q, 8-K Forms - Stock Titan
SNGX Earnings History & Surprises | EPS & Revenue Results | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill
SNGX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Soligenix (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behcet Disease - Digital Journal
Soligenix (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit - Digital Journal
Soligenix's (NASDAQ: SNGX) SGX945 Shows Promise with Immune-Modulating Approach - Digital Journal
Analysts Have Conflicting Sentiments on These Healthcare Companies: Certara (CERT), Soligenix (SNGX) and Day One Biopharmaceuticals (DAWN) - The Globe and Mail
Soligenix receives positive EMA opinion for orphan drug status - Investing.com Australia
Biopharmaceutical company Soligenix, Inc. recently announced that its application for orphan drug designation for SGX945, developed for the treatment of Behçet's Disease, has received a positive opinion from the European Medicines Agency (EMA). - Bitget
Soligenix receives positive EMA opinion for orphan drug status By Investing.com - Investing.com UK
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease - Nasdaq
Soligenix (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behçet Disease - The Globe and Mail
SNGX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Growth Value: Is Soligenix Inc a speculative investmentOil Prices & Risk Managed Investment Strategies - baoquankhu1.vn
Soligenix to Present at BIO Investment Summit - Intellectia AI
Soligenix to Present at BIO Investment & Growth Summit - PR Newswire
SNGX PE Ratio & Valuation, Is SNGX Overvalued - Intellectia AI
Will Soligenix Inc. face regulatory challenges2025 Stock Rankings & Proven Capital Preservation Methods - mfd.ru
Why Levi Strauss Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket - Intellectia AI
Armistice Capital and Steven Boyd report 4.99% stake in Soligenix (SNGX) - Stock Titan
Why Soligenix Inc. stock is favored by top institutions2025 Key Lessons & Proven Capital Preservation Tips - mfd.ru
Soligenix, Inc. Announces Adjournment of Annual Meeting, Informa - GuruFocus
Will Soligenix Inc. stock split attract more investors2025 Geopolitical Influence & AI Forecasted Stock Moves - mfd.ru
Analysts Offer Insights on Healthcare Companies: Soligenix (SNGX) and Boston Scientific (BSX) - The Globe and Mail
Soligenix Inc Azioni (SNGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):